BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 17, 2010
View Archived Issues
NPS Pharmaceuticals Rakes in $38.6M to Advance Pipeline
Read More
Actis Biologics to Raise $380M, for Malaysia, India Ventures
Read More
FDA Panel Backs Alkermes Drug Vivitrol for Opioid Dependence
Read More
Stock Movers
Read More
Forest to Pay $313M to Settle Unapproved Drug Charges
Read More
Clinic Roundup
Read More
Other News To Note
Read More
FDA Panel Rejects Arena's Weight Loss Drug Lorcaserin
ADELPHI, Md. – An FDA panel Thursday said the potential risks of tumors, psychiatric effects and heart problems outweighed any benefits of weight loss with Arena Pharmaceuticals Inc.'s Lorquess (lorcaserin). (BioWorld Today)
Read More
Size Matters: Virtual Firms Run Lean, Struggle for Exits
Read More